Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVB vs IVB + Suprachoroidal Triamcinolone for DME
NCT06882551Phase 4Completed
- Sponsor
- Khyber Teaching Hospital
- Start
- Apr 2023
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of triamcinolone in diabetic macular edema (DME) (2 arms), sponsored by Khyber Teaching Hospital. Primary endpoints: Central Macular Thickness at 3 months and Visual Acuity at 3 months. Started Apr 2023; status: completed.
02
Drugs
triamcinolone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06882551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06882551.